Adrenoleukodystrophy (ALD) Cell Models for Research

Adrenoleukodystrophy (ALD) is an X-linked peroxisomal disorder caused by mutations in the ABCD1 gene, affecting approximately 1 in 17,000 individuals worldwide (WHO, 2023). The disease predominantly affects males, with a median age of onset for the childhood cerebral form at 7 years, leading to progressive neurodegeneration and death within 2-5 years without treatment. The adult form, adrenomyeloneuropathy, presents in the 20s-30s with spinal cord and peripheral nerve involvement. Hematopoietic stem cell transplantation can halt cerebral disease if performed early, but outcomes remain poor for advanced cases. The global burden is significant, with an estimated 20,000-50,000 affected males worldwide, and carrier females may exhibit milder symptoms. Research is critical to develop targeted therapies and biomarkers for early diagnosis and monitoring.

ALD is an ideal model for studying peroxisomal dysfunction, lipid metabolism, and neurodegeneration. The monogenic nature of the disease allows for precise genetic modeling using CRISPR. Key research questions include the pathophysiology of very long-chain fatty acid (VLCFA) accumulation, the role of oxidative stress and mitochondrial dysfunction, and the mechanisms of neuroinflammation. Public datasets, such as those from the NCBI Gene Expression Omnibus (GEO), provide transcriptomic profiles of patient-derived cells and animal models, enabling systems-level analyses. The availability of patient-derived fibroblasts and induced pluripotent stem cells (iPSCs) further enhances the translational relevance of in vitro models.

The primary defect in ALD is the impaired import of very long-chain fatty acids (VLCFAs) into peroxisomes for beta-oxidation, due to mutations in the ABCD1 gene encoding the peroxisomal transporter. This leads to accumulation of VLCFAs, particularly hexacosanoic acid (C26:0), in tissues and plasma. The accumulation triggers a cascade of cellular damage:

1. VLCFA accumulation: Excess VLCFAs incorporate into cell membranes, altering membrane fluidity and function.

2. Oxidative stress: VLCFA accumulation induces reactive oxygen species (ROS) production, leading to oxidative damage to lipids, proteins, and DNA.

3. Mitochondrial dysfunction: Impaired mitochondrial function and energy metabolism contribute to cellular degeneration.

4. Neuroinflammation: Activated microglia and astrocytes release pro-inflammatory cytokines, causing demyelination and axonal loss.

These pathways are interconnected and provide multiple targets for therapeutic intervention.

Data from ClinVar and NCBI Gene indicate over 800 distinct mutations in ABCD1, with no clear genotype-phenotype correlation. The most common mutations are missense variants, but large deletions and insertions also occur. The lack of correlation suggests that environmental and modifier genes influence disease severity.

The pathogenic pathways in ALD involve several signaling networks:

• • PPAR signaling: VLCFAs act as ligands for PPARs, particularly PPARα, which regulates lipid metabolism genes. Altered PPAR signaling may contribute to metabolic dysregulation.
• • NF-κB pathway: Oxidative stress and VLCFA accumulation activate NF-κB, leading to pro-inflammatory gene expression in microglia and astrocytes.
• • MAPK/ERK pathway: VLCFAs can activate MAPK signaling, promoting cell proliferation or apoptosis depending on context.
• • PI3K/AKT pathway: Impaired insulin signaling and altered AKT activation have been observed, affecting cell survival and metabolism.
• • mTOR signaling: Dysregulated mTOR activity may influence autophagy and cellular stress responses.

These networks offer potential targets for pharmacological intervention.

Organoids derived from patient iPSCs, such as cerebral organoids, recapitulate the three-dimensional architecture of the brain and can model the neurodevelopmental aspects of ALD. They are valuable for studying cell-cell interactions and testing therapeutic agents.

• • ABCD1 knockout mouse: The most commonly used model, exhibiting VLCFA accumulation and mild neurological phenotype, but not the severe cerebral demyelination seen in humans.
• • ABCD1/ABCD2 double knockout mouse: More severe phenotype, with axonal degeneration and behavioral deficits.
• • Patient-derived xenograft (PDX) models: Not typically used for ALD due to the lack of tumor involvement; however, xenografts of patient-derived cells into immunodeficient mice can be used to study disease mechanisms.
• • Induced models: Chemical induction of VLCFA accumulation using erucic acid or other agents can mimic some aspects of ALD in wild-type animals.

These models are essential for preclinical testing of gene therapies and pharmacological interventions.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise ABCD1 mutations, providing powerful tools for studying ALD. For example:

• • ABCD1 knockout cell lines: Generated by introducing frameshift mutations via CRISPR-Cas9, resulting in complete loss of function. These lines are useful for studying the consequences of ABCD1 deficiency in various cell types, such as neurons, glia, and fibroblasts.
• • ABCD1 point mutation knock-in lines: Specific patient mutations (e.g., p.Arg617His) can be introduced into wild-type cells to study genotype-phenotype correlations and test mutation-specific therapies.
• • Reporter lines: ABCD1 promoter-driven fluorescent reporters can be used to monitor gene expression in real time.

These gene-edited models are commercially available from several suppliers and are sequence-verified, ensuring reproducibility. They accelerate research by providing consistent, well-characterized models that can be used for high-throughput screening and mechanistic studies.

Gene-edited cell lines are essential for functional genomics studies. For example, ABCD1 knockout lines can be used to identify downstream effectors of VLCFA accumulation by transcriptomic and proteomic profiling. CRISPR screens can be performed in these lines to identify genes that modify the phenotype, such as those involved in lipid metabolism or oxidative stress response. Additionally, complementation studies with wild-type ABCD1 can confirm the specificity of the phenotype.

Isogenic pairs (wild-type vs. ABCD1 knockout) are ideal for drug screening. Compounds that reduce VLCFA levels or mitigate oxidative stress can be identified by comparing the response of mutant and wild-type cells. Resistance mechanisms can be studied by exposing cells to increasing concentrations of a drug and selecting for resistant clones, then identifying genetic or epigenetic changes. This approach can reveal potential resistance pathways and guide combination therapies.

CRISPR-based synthetic lethality screens can identify genes that are essential only in ABCD1-deficient cells. These genes may serve as biomarkers for disease progression or as therapeutic targets. For example, if a gene is required for survival of ABCD1 knockout cells but not wild-type cells, inhibiting that gene could selectively kill diseased cells. Such screens can be performed using pooled CRISPR libraries and next-generation sequencing to identify hits.